Reviews/Osteoporosis Fracture Prevention/Post-denosumab bisphosphonate bone loss
Anabolic And Sequential Therapy · ostfrac_10 · v2
When denosumab is stopped, bone density can fall sharply and fractures can follow. This corpus shows that giving a bisphosphonate afterwards does reduce that bone loss compared with no treatment, and that it lowers the chance of spinal fractures [1][2][8][12]. But the drug matters: alendronate and zoledronate work while risedronate does not [2], and how long someone was on denosumab matters too, because protection is good after short-term use but incomplete after long-term use [3][5][7][21]. Several studies show bone loss and the biochemical rebound still happen despite bisphosphonate treatment [3][5][21]. For those reasons the panel treated the flat word 'prevents' as too strong and landed on a conditional reading: bisphosphonates mitigate rebound bone loss, depending on the agent, the timing, and prior denosumab duration.
Versus no treatment, bisphosphonates reduce post-denosumab BMD loss: delayed intravenous zoledronate retained 73% of spine and 87% of hip gains a year later while untreated patients lost 80-90% [1]; alendronate and zoledronate mitigated loss where no treatment and risedronate did not [2]; and most patients maintained BMD after transitioning to alendronate [8]. Protection can be durable, with more than half of women holding BMD gains five years after a single zoledronate infusion [4]. A retrospective registry of 797 cases found bisphosphonates after denosumab were protective against vertebral fractures [12]. However the effect is incomplete after longer denosumab exposure: two zoledronate infusions did not prevent BMD loss or fracture when CTX stayed high (spine -5.5%) [3], alendronate did not consistently attenuate loss (lumbar spine -5.9%) [5], early and multiple zoledronate doses were needed in long-term users [7], and the CTX rebound was only partially mitigated by zoledronate [21]. The contested point: The division is over the word 'prevents' versus 'mitigates': the direction of benefit is consistent, but whether bisphosphonates abolish rebound bone loss or merely attenuate it splits the corpus, with the preserving studies concentrated after short-term denosumab [1][8] and the incomplete-prevention studies after long-term denosumab [3][5][7][21]. The agent chosen (risedronate failing in [2]) and the reliance on BMD rather than fracture endpoints sharpen the disagreement.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim word 'prevents' overreaches the corpus: four primary studies [3][5][7][21] show rebound bone loss and biochemical rebound are attenuated but not abolished, with significant BMD decline persisting despite bisphosphonate. The defensible claim is 'mitigates', not 'prevents'.
Prior denosumab duration is an uncontrolled modifier: preservation is good after short-term denosumab [1][8] but prevention fails after long-term use [3][7]. The claim does not qualify for duration, so it generalises a conditional effect.
Where it remains uncertain. After long-term denosumab, significant BMD loss and biochemical rebound persist despite bisphosphonate dosing [3][5][7][21], and risedronate fails outright [2], so the absolute word 'prevents' is not supported.
Aleatory
Within single-agent cohorts some patients maintain and others lose BMD, e.g. at month 12 only a minority lost BMD on alendronate at each site [8] and 7 of 19 became osteoporotic again after single zoledronate [4].
Epistemic
Whether bisphosphonates can prevent loss after longer denosumab exposure is explicitly unresolved — [4] states applicability to longer-treated patients remains to be established and [7] shows incomplete preservation in long-term users.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Supports: delayed IV zoledronate after short-term denosumab retains most BMD benefit vs 80-90% loss untreated.
“In these women, spine BMD was 17.3% above baseline at trial-end, and still 12.3% above baseline a year later, a 73% (CI: 61%, 85%) retention of the treatment benefit.”
Panel auditInternal validity: low · scope of inference: Postmenopausal women transitioning off short-term (3-year) denosumab in the FRAME trial, treated with delayed IV zoledronate.Key limitations: tiny sample · non-randomized treatment choice · short prior denosumab exposure · rising PINP suggests repeat dosing needed
Supports direction but qualifies: effect is agent-specific; risedronate does not work.
“Subsequent treatment with ALN or ZOL but not NT and RIS mitigates BMD loss after Dmab discontinuation.”
Panel auditInternal validity: medium · scope of inference: Older patients (mean 71 years) discontinuing denosumab after mean 5.4 doses, 1-year BMD outcome.Key limitations: retrospective · modest per-arm n · risedronate not protective · no blinding
Supports durability but only in 'more than half' — not full prevention.
“more than half of the osteoporotic women who became osteopenic with denosumab treatment and stopped it, maintained the BMD gains 5 years after a single zoledronate infusion with no additional treatment.”
Panel auditInternal validity: low · scope of inference: Postmenopausal women who became osteopenic on ~2.4 years of denosumab then stopped, given single zoledronate.Key limitations: no control arm in extension · small n · short prior denosumab duration · one-third relapsed to osteoporosis
Counter-evidence: zoledronate did not prevent BMD loss or fractures in high-turnover patients.
“In patients with uncontrolled CTX levels after Dmab withdrawal, 2 ZOL infusions 6 months apart do not prevent BMD loss and FX.”
Panel auditInternal validity: medium · scope of inference: Patients managed by ECTS CTX-guided repeated-zoledronate protocol, average 17 months after denosumab withdrawal.Key limitations: retrospective · small sample · selection by CTX response · subgroup with persistently high turnover
4 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus robustly supports the direction of effect but repeatedly contradicts the claim's implication of full prevention, warranting an Uncertain tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Fracture-powered RCT of bisphosphonate after denosumab. Hard fracture prevention — the clinically important outcome — rests on one retrospective registry [12] and low-event counts [5][21], not a prospective trial. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized controlled trial with rebound vertebral fracture as the primary endpoint, comparing a potent bisphosphonate regimen against no treatment or placebo after denosumab cessation.
Open question: Can any bisphosphonate regimen prevent, rather than only attenuate, rebound bone loss after long-term denosumab? Why it is still open: After long-term denosumab, significant BMD loss and biochemical rebound persist despite standard and repeated bisphosphonate dosing [3][5][7][21].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19